A composition includes a target pharmaceutical or biological agent, a solution containing the target pharmaceutical or biological agent, and substrate that is soluble in the solution. The substrate is capable of being solidified via a solidification process and the solidification process causes the substrate to become physically or chemically cross-linked, vitrified, or crystallized. As a result of the solidification process, particles are formed. The target pharmaceutical or biological agent within the solution retains proper conformation to ultimately produce a desired effect.

A process is disclosed herein comprising the step of contacting an esterifying agent and a polysaccharide in the presence of a solvent and suitable reaction conditions for a reaction time sufficient to form a product comprising a polysaccharide ester composition, wherein the polysaccharide ester composition comprises a polysaccharide ester having a degree of substitution of about 0.001 to about 3; wherein the esterifying agent comprises an acyl halide, a phosphoryl halide, a carboxylic acid anhydride, a haloformic acid ester, a carbonic acid ester, or a vinyl ester; and the ratio of esterifying agent to polysaccharide is in the range of about 0.001:1 to about 3:1 on a molar equivalent basis. In one embodiment, the polysaccharide comprises poly alpha-1,3-glucan.

In one aspect, the disclosure provides methods of distinguishing a glycosaminoglycan from one or more other components in a sample by subjecting the sample to size-exclusion chromatography using a mobile phase having a pH of 6.8 or lower. A mobile phase having a pH of 6.8 or lower is found to improve the separation of glycosaminoglycans from proteins during size exclusion chromatography. In some embodiments, improved separation is due to the low pH of the mobile phase causing elution of less dispersed fractions of the protein and/or glycosaminoglycan. In some embodiments, the overlap between protein and/or glycosaminoglycan fractions is reduced.

Compositions are disclosed herein comprising a graft copolymer that comprises: (i) a backbone comprising dextran that has been modified with about 1%-25% alpha-1,2 branches, and (ii) one or more alpha-1,3-glucan side chains comprising at least about 50% alpha-1,3 glycosidic linkages. Further disclosed are reactions for producing such graft copolymers, as well as their use in derivatives, films and various other applications.

Provided are methods of attaching a mannose-binding C-type lectin receptor targeting moiety to a polymeric carbohydrate backbone using an amide linkage. The amide linkage may be found between a leash, such as an amine terminated leash, and the mannose-binding C-type lectin receptor targeting moieties. The compounds and compositions disclosed utilizing the amide linkage provide for highly stable compounds with a significant reduction in loss of mannose-binding C-type lectin receptor targeting moieties from the polymeric carbohydrate backbone.

The present application relates to a lyophilized scaffold composition having at least one polysaccharide wherein said scaffold is substantially solid and capable of being formed into a desired shape; wherein the at least one polysaccharide has a protonation level resulting in controlled rehydration of said scaffold, such that when said scaffold is contacted with at least one of a neutral aqueous solution, blood, blood derived fluid and combinations thereof, said scaffold forms a microparticle dispersion and stimulates tissue remodeling and anabolic wound repair, a process for preparing a lyophilized scaffold composition and the use of a lyophilized scaffold composition for wound repair in a mammal.

The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimes saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.

A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glucose unit within an interval of 2.5 and 3.0. Furthermore, an average sulfation of C2 position in the glucose units of the dextran sulfate, or the salt thereof, is at least 90%. The dextran sulfate has improved biological effects and/or reduced toxicity as compared to similar dextran sulfate molecules available on the market.

Compositions are disclosed herein comprising poly alpha-1,3-1,6-glucan with a weight average degree of polymerization (DP.sub.w) of at least 1000. This glucan polymer comprises at least 30% alpha-1,3 linkages and at least 30% alpha-1,6 linkages. Further disclosed are glucosyltransferase enzymes that synthesize poly alpha-1,3-1,6-glucan. Ether derivatives of poly alpha-1,3-1,6-glucan and methods of using such derivatives as viscosity modifiers are also disclosed.

The present invention is directed to compositions and methods for dust control in particular in industrial operations such as mining. More particularly, the dust controlling agents are functionalized polysaccharides, partially oxidized polysaccharides that may or may not also be functionalized, or salts thereof.